Prosecution Insights
Last updated: May 29, 2026
Application No. 18/412,997

CYCLOSILAZANE PRECURSORS AND RELATED METHODS

Non-Final OA §102§112
Filed
Jan 15, 2024
Priority
Jan 17, 2023 — provisional 63/439,331
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Entegris Inc.
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
65%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1422 granted / 1758 resolved
+20.9% vs TC avg
Minimal -16% lift
Without
With
+-15.6%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
46 currently pending
Career history
1800
Total Applications
across all art units

Statute-Specific Performance

§101
2.3%
-37.7% vs TC avg
§103
18.5%
-21.5% vs TC avg
§102
21.4%
-18.6% vs TC avg
§112
27.8%
-12.2% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1758 resolved cases

Office Action

§102 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-20 are pending in the application. Claim Rejections - 35 USC § 112 3. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-9 and 16-17 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. In independent claims 1 and 16, the term - - A precursor comprising - - - is vague and indefinite since it is not clear whether precursor is represented by this compound (5-membered ring containing 2N and 3Si atoms) or some other larger compound of unknown structure having this compound embedded somewhere. Claim 2 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 3 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 4 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 5 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 6 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 7 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 8 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim 9 recites the limitation "composition" in claim 1. There is insufficient antecedent basis for this limitation in the claim. Claim Rejections - 35 USC § 102 (a)(1) the claimed invention was patented, described in a printed publication, or in public use, on sale, or otherwise available to the public before the effective filing date of the claimed invention. Claims 1, 3-6, 8-10 and 12-15 are rejected under 35 U.S.C. 102(a) (1) as being anticipated by Wannagat (Zeitsch. Fuer. Anorgan. and Allgem. Chem.). Wannagat discloses silicon-nitrogen compounds and a process for preparing these compounds. The compounds B5 and B6 and a process for preparing these compounds (see page 49) disclosed by Wannagat anticipate the instant claims when variables R1-R5 represent methyl group or R1, R2, R4 and R5 represents methyl group and variable R3 represents propyl group in the instant compounds. Claims 1, 3-4 and 8 are rejected under 35 U.S.C. 102(a) (1) as being anticipated by compound with RN 133823-16-2. The compound with RN 133823-16-2 was entered in STN on May 17, 1991 and therefore, anticipates the instant claims when variable R3 represents H and variables R1, R2, R4 and R5 represent methyl group in the instant claims. It is of note that these claims are directed to product by process and therefore, process is irrelevant. Allowable Subject Matter Claims 11 and 18-20 are objected to as being dependent upon a rejected base claim, but would be allowable if rewritten in independent form including all of the limitations of the base claim and any intervening claims. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Jan 15, 2024
Application Filed
Mar 02, 2026
Non-Final Rejection mailed — §102, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12636278
HDAC6-INHIBITED HUMAN REGULATORY T CELLS
3y 10m to grant Granted May 26, 2026
Patent 12637464
TETRACYCLIC COMPOUNDS FOR TREATING BRAIN DISORDERS
2y 7m to grant Granted May 26, 2026
Patent 12629337
DAPTOMYCIN FORMULATION
3y 10m to grant Granted May 19, 2026
Patent 12625144
CHEMOSELECTIVE SENSITIVITY BOOSTER FOR TAGGING A PEPTIDE, PEPTIDE CONJUGATE, OR SIMILAR REACTIVE MOLECULE
4y 5m to grant Granted May 12, 2026
Patent 12624042
COMPOUND FOR TARGETED DEGRADATION OF BTK AND ANTI-TUMOUR USE THEREOF
3y 0m to grant Granted May 12, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
65%
With Interview (-15.6%)
2y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1758 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month